Morgan Stanley Lineage Cell Therapeutics, Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 837,463 shares of LCTX stock, worth $1.41 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

837,463

Previous 968,781 13.55%

Holding current value

$1.41 Million

Previous $435,000 75.17%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	SELL	$0.39 - $1.13 $51,214 - $148,389	-131,318 Reduced 13.55%	837,463 $762,000
Q1 2025 May 15, 2025	BUY	$0.45 - $0.72 $138,924 - $222,278	308,720 Added 46.77%	968,781 $435,000
Q4 2024 Feb 14, 2025	SELL	$0.5 - $0.95 $94,115 - $178,818	-188,230 Reduced 22.19%	660,061 $330,000
Q3 2024 May 14, 2025	BUY	$0.8 - $1.12 $257,329 - $360,261	321,662 Added 61.08%	848,291 $771,000
Q3 2024 Nov 14, 2024	BUY	$0.8 - $1.12 $257,329 - $360,261	321,662 Added 61.08%	848,291 $771,000
Q2 2024 May 14, 2025	SELL	$0.89 - $1.47 $118,754 - $196,145	-133,432 Reduced 20.22%	526,629 $526,000
Q2 2024 Oct 17, 2024	BUY	$0.89 - $1.47 $60,459 - $99,860	67,932 Added 14.81%	526,629 $526,000
Q2 2024 Aug 14, 2024	BUY	$0.89 - $1.47 $60,459 - $99,860	67,932 Added 14.81%	526,629 $526,000
Q1 2024 Oct 17, 2024	SELL	$0.86 - $1.48 $58,421 - $100,539	-67,932 Reduced 12.9%	458,697 $678,000
Q1 2024 Aug 16, 2024	SELL	$0.86 - $1.48 $16,227 - $27,926	-18,869 Reduced 3.95%	458,697 $678,000
Q1 2024 May 15, 2024	SELL	$0.86 - $1.48 $16,227 - $27,926	-18,869 Reduced 3.95%	458,697 $678,000
Q4 2023 Aug 16, 2024	SELL	$0.91 - $1.35 $44,647 - $66,235	-49,063 Reduced 9.32%	477,566 $520,000
Q4 2023 Feb 13, 2024	BUY	$0.91 - $1.35 $181,772 - $269,662	199,750 Added 71.9%	477,566 $520,000
Q3 2023 Nov 15, 2023	BUY	$1.16 - $1.53 $145,680 - $192,148	125,587 Added 82.5%	277,816 $327,000
Q2 2023 Aug 14, 2023	SELL	$1.26 - $1.53 $193,902 - $235,453	-153,891 Reduced 50.27%	152,229 $214,000
Q1 2023 May 15, 2023	BUY	$1.2 - $1.53 $209,192 - $266,720	174,327 Added 132.27%	306,120 $459,000
Q4 2022 Feb 14, 2023	BUY	$1.02 - $1.5 $70,615 - $103,846	69,231 Added 110.66%	131,793 $154,000
Q3 2022 Nov 14, 2022	SELL	$1.13 - $1.77 $74,967 - $117,427	-66,343 Reduced 51.47%	62,562 $70,000
Q2 2022 Oct 27, 2022	SELL	$1.12 - $1.61 $129,080 - $185,552	-115,250 Reduced 47.2%	128,905 $203,000
Q2 2022 Aug 15, 2022	SELL	$1.12 - $1.61 $129,080 - $185,552	-115,250 Reduced 47.2%	128,905 $203,000
Q1 2022 Oct 27, 2022	BUY	$1.21 - $2.48 $139,452 - $285,820	115,250 Added 89.41%	244,155 $376,000
Q1 2022 May 13, 2022	SELL	$1.21 - $2.48 $344,126 - $705,316	-284,402 Reduced 53.81%	244,155 $376,000
Q4 2021 Feb 14, 2022	BUY	$1.84 - $2.68 $741,913 - $1.08 Million	403,214 Added 321.69%	528,557 $1.3 Million
Q3 2021 Nov 15, 2021	BUY	$2.26 - $2.86 $283,275 - $358,480	125,343 New	125,343 $316,000

Others Institutions Holding LCTX

# of Institutions

140

Shares Held

106M

Call Options Held

368K

Put Options Held

View Full List

About Lineage Cell Therapeutics, Inc.

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $285M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

More about LCTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account